Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma

Keyphrases

• Multiple Myeloma 100%
• Protease Inhibitors 100%
• Carfilzomib 100%
• Bortezomib 50%
• Relapsed or Refractory multiple Myeloma 25%
• Overall Response Rate 12%
• Anemia 12%
• Nausea 12%
• Peripheral Neuropathy 12%
• Median Overall Survival 12%
• Proteasome Inhibition 12%
• Clinical Efficacy 12%
• Phase II Study 12%
• Immunosuppressive Agents 12%
• Treatment Regimen 12%
• Thrombocytopenia 12%
• Dyspnea 12%
• Duration of Response 12%
• Consecutive Days 12%
• Heavily Pretreated Patients 12%
• Lenalidomide 12%
• Relapsed Disease 12%
• Body Surface Area 12%
• Rest Period 12%
• Pharmacology 12%
• Safety Self-efficacy 12%
• Overall Survival Time 12%
• Place in Therapy 12%
• 26S Proteasome 12%
• Thalidomide 12%
• Irreversible Inhibitor 12%
• Safety Cost 12%
• Adverse Effect Profile 12%
• Actual Body 12%

Medicine and Dentistry

• Multiple Myeloma 100%
• Proteasome Inhibitor 100%
• Carfilzomib 100%
• Bortezomib 50%
• Proteasome 37%
• Health Care Cost 25%
• Nausea 12%
• Adverse Event 12%
• Infusion 12%
• Anemia 12%
• Overall Survival 12%
• Disease 12%
• Clinical Study 12%
• Neuropathy 12%
• Thrombocytopenia 12%
• Lenalidomide 12%
• Dyspnea 12%
• Survival Time 12%
• Thalidomide 12%
• Body Surface 12%

Pharmacology, Toxicology and Pharmaceutical Science

• Multiple Myeloma 100%
• Proteasome Inhibitor 100%
• Carfilzomib 100%
• Bortezomib 50%
• Proteasome 37%
• Disease 12%
• Anemia 12%
• Nausea 12%
• Adverse Event 12%
• Overall Survival 12%
• Clinical Study 12%
• Thrombocytopenia 12%
• Dyspnea 12%
• Lenalidomide 12%
• Survival Time 12%
• Neuropathy 12%
• Clinical Pharmacology 12%
• Thalidomide 12%